Therapeutic Evaluation of Low-dose IL-2-based Immunomodulatory Approach in Patients With Early AD
Status:
Not yet recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
Study aims at evaluating the therapeutic efficacy and safety of low-dose IL-2
immunomodulatory treatment in patients with early AD, in a phase II, randomized, double
blind, placebo-controlled phase II clinical trial. Patients with AD at early stage will be
recruited and randomized (2:1) in each treatment group.
The primary endpoint is the rate of decline assessed through CDR change at 18 months between
the placebo group and the treated patients.